醋酸泼尼松联合来氟米特治疗IgA肾病的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 醋酸泼尼松联合来氟米特治疗IgA肾病的临床观察
TITLE:
摘要: 目的:观察醋酸泼尼松联合来氟米特治疗免疫球蛋白A(IgA)肾病的疗效及安全性。方法:选取IgA肾病患者80例,按随机数字表法分为观察组和对照组,各40例。对照组患者给予醋酸泼尼松1.0 mg/kg,qd,6周后逐渐减量,至12周时降至0.5 mg/kg;观察组患者在对照组基础上加用来氟米特50 mg,qd,3 d后降至20 mg。两组患者均治疗3个月。观察两组患者治疗后临床疗效及24 h尿蛋白定量、血肌酐(SCr)、血尿素氮(BUN)水平,并记录治疗过程中的不良反应情况。结果:观察组患者总有效率(95.0%)显著高于对照组(75.0%),差异有统计学意义(P<0.05);治疗后,两组患者的24 h尿蛋白定量、SCr、BUN水平均显著降低,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组患者的不良反应发生率(0)显著低于对照组(7.5%),差异有统计学意义(P<0.05)。结论:醋酸泼尼松联合来氟米特治疗IgA肾病患者效果显著,且不会增加患者的不良反应。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy and safety of prednisone acetate combined with leflunomide in the treatment of IgA nephropathy. METHODS: 80 patients with IgA nephropathy were randomly divided into observation group and control group, with 40 cases in each group. Control group was given prednisone acetate 1.0 mg/kg, qd, 6 weeks later, decreasing gradually, decreasing to 0.5 mg/kg in 12th week; observation group was additionally given leflunomide 50 mg, qd, 3 days later decreasing to 20 mg. Both groups were given 3 months of treatment. Clinical efficacy, 24 h urinary protein quantification, Scr and BUN levels were observed in 2 groups after treatment, and ADR were recorded during treatment. RESULTS: Total effective rate of observation group (95.0%) was significantly higher than that of control group (75.0%), with statistical significance (P<0.05). After treatment, 24 h urinary protein quantification, Scr and BUN levels of observation group were significantly lower than those of control group, with statistical significance (P<0.05). The incidence of ADR in observation group (0) was significantly lower than in control group (7.5%), with statistical significance (P<0.05). CONCLUSIONS: Prednisone acetate combined with leflunomide has significant effect on IgA nephropathy, and will not increase the occurrence of ADR.
期刊: 2016年第27卷第8期
作者: 李登峰,任金香
AUTHORS: LI Dengfeng,REN Jinxiang
关键字: 醋酸泼尼松;来氟米特;免疫球蛋白A肾病;安全性
KEYWORDS: Prednisone acetate; Leflunomide; IgA nephropathy; Effectiveness
阅读数: 379 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!